Improving treatment retention for addiction after serious infections
Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN): A Pilot Randomized Controlled Study
This study tests a new support program for people with opioid use disorder who are hospitalized for serious infections to see if it helps them stick with their treatment and recover better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Boston Medical Center Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06489535 on ClinicalTrials.gov |
What this trial studies
This pilot project tests an adapted intervention called Recovery Management Checkups (RMC) for individuals hospitalized with serious injection related infections (SIRI) and opioid use disorder (OUD). The intervention aims to address the unique challenges faced by these patients to improve their long-term treatment retention with medications for OUD. By assessing feasibility and acceptability, the study seeks to gather early findings on the efficacy of this tailored approach. The ultimate goal is to enhance recovery outcomes and reduce re-hospitalizations among this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 who are hospitalized for serious injection related infections and can provide informed consent.
Not a fit: Patients who are unable to provide informed consent or are in police custody may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve long-term treatment retention and recovery outcomes for patients with opioid use disorder following serious infections.
How similar studies have performed: While this approach is adapted from existing interventions, it specifically targets a unique patient population, making it a novel application in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Between 18 and 65 years of age * Able to provide Informed Consent * Admitted to Boston Medical Center on any inpatient unit for an active serious injection related infection (SIRI) such as endocarditis, osteomyelitis, bacteremia, septic arthritis, epidural abscess or other serious infection in which two weeks or more of antibiotics are recommended Exclusion Criteria: * Not able to give informed consent * Cognitive ability (defined through Research Assistant (RA) determination) * Inability to complete assessments in English or Spanish (defined through RA determination). * Exclusion for any reason under PI discretion * Unable to provide names and contact information for at least two verifiable locator persons who will know where to find them in the future. * In police custody or expecting incarceration
Where this trial is running
Boston, Massachusetts
- Boston Medical Center — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Simeon Kimmel, MD — Boston Medical Center
- Study coordinator: Simeon Kimmel, MD
- Email: Simeon.Kimmel@bmc.org
- Phone: 617-414-6927
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.